RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins.
HMGA2
Pituitary adenomas
RPSAP52
lncRNA
microRNA
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
10
09
2018
accepted:
17
04
2019
revised:
08
04
2019
pubmed:
12
5
2019
medline:
20
6
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
Long non-coding RNAs (lncRNAs) are emerging as fundamental players in cancer biology. Indeed, they are deregulated in several neoplasias and have been associated with cancer progression, tumor recurrence, and resistance to treatment, thus representing potential biomarkers for cancer diagnosis, prognosis, and therapy. In this study, we aimed to identify lncRNAs associated with pituitary tumorigenesis. We have analyzed the lncRNA expression profile of a panel of gonadotroph pituitary adenomas in comparison with normal pituitaries. Then, we focused on RPSAP52, a novel lncRNA antisense for the HMGA2 gene, whose overexpression plays a critical role in the development of pituitary adenomas. We report that RPSAP52 expression is highly upregulated in gonadotroph and prolactin-secreting pituitary adenomas, where it correlates with that of HMGA2, compared with normal pituitary tissues. Conversely, its expression showed a variable behavior in somatotroph adenomas. We also demonstrate that RPSAP52 enhances HMGA2 protein expression in a ceRNA-dependent way acting as sponge for miR-15a, miR-15b, and miR-16, which have been already described to be able to target HMGA2. Interestingly, RPSAP52 also positively modulates HMGA1, the other member of the High-Mobility Group A family. Moreover, functional studies indicate that RPSAP52 promotes cell growth by enhancing the G1-S transition of the cell cycle. The results reported here reveal a novel mechanism, based on the overexpression of the lncRNA RPSAP52, which contributes to pituitary tumorigenesis, and propose this lncRNA as a novel player in the development of these tumors. KEY MESSAGES: RPSAP52 is overexpressed in pituitary adenomas. RPSAP52 increases HMGA protein levels. A ceRNA mechanism is proposed for the increased HMGA1/2 expression.
Identifiants
pubmed: 31076808
doi: 10.1007/s00109-019-01789-7
pii: 10.1007/s00109-019-01789-7
doi:
Substances chimiques
HMGA Proteins
0
MicroRNAs
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019-1032Références
Korbonits M, Carlsen E (2009) Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res 71(Suppl 2):123–130
pubmed: 19407508
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613–619
doi: 10.1002/cncr.20412
pubmed: 15274075
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769–4775
doi: 10.1210/jc.2006-1668
pubmed: 16968795
Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377–382
doi: 10.1111/j.1365-2265.2009.03667.x
Trouillas J (2014) In search of a prognostic classification of endocrine pituitary tumors. Endocr Pathol 25:124–132
doi: 10.1007/s12022-014-9322-y
pubmed: 24839229
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688–1695
doi: 10.1056/NEJM199112123252403
pubmed: 1944469
Chahal HS, Stals K, Unterländer M, Balding DJ, Thomas MG, Kumar AV, Besser GM, Atkinson AB, Morrison PJ, Howlett TA, Levy MJ, Orme SM, Akker SA, Abel RL, Grossman AB, Burger J, Ellard S, Korbonits M (2011) AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med 364:43–50
doi: 10.1056/NEJMoa1008020
pubmed: 21208107
Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y, Tanaka K, Wieland T, Graf E, Saeger W, Ronchi CL, Allolio B, Buchfelder M, Strom TM, Fassnacht M, Komada M (2015) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 47:31–38
doi: 10.1038/ng.3166
pubmed: 25485838
Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, Valtorta E, Mortini P, Croce CM, Larizza L, Fusco A (2002) The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res 62:2398–2405
pubmed: 11956103
Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E et al (2002) Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21:3190–3198
doi: 10.1038/sj.onc.1205428
pubmed: 12082634
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458:223–227
doi: 10.1038/nature07672
pubmed: 19182780
pmcid: 2754849
Palmieri D, D’Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A, Fedele M, Trouillas J, Fusco A (2012) Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 31:3857–3865
doi: 10.1038/onc.2011.557
pubmed: 22139073
D’Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J, Fusco A (2012) Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab 97:E1128–E1138
doi: 10.1210/jc.2011-3482
pubmed: 22564666
Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM et al (2006) HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9:459–471
doi: 10.1016/j.ccr.2006.04.024
pubmed: 16766265
Müssnich P, Raverot G, Jaffrain-Rea ML, Fraggetta F, Wierinckx A, Trouillas J, Fusco A, D’Angelo D (2015) Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. Cell Cycle 14:2590–2597
doi: 10.1080/15384101.2015.1064207
pubmed: 26125663
pmcid: 4614981
Spizzo R, Almeida MI, Colombatti A, Calin GA (2012) Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 31:4577–4587
doi: 10.1038/onc.2011.621
pubmed: 22266873
pmcid: 3433647
Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9:703–719
doi: 10.4161/rna.20481
pubmed: 22664915
pmcid: 3495743
Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12:861–874
doi: 10.1038/nrg3074
pubmed: 22094949
Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A (2003) A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88:5119–5126
doi: 10.1210/jc.2003-030222
pubmed: 14602737
Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH (2015) Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol 36:4851–4859
doi: 10.1007/s13277-015-3139-2
pubmed: 25636452
Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, Xie WP, Hou YY (2013) Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 13:461
doi: 10.1186/1471-2407-13-461
pubmed: 24098911
pmcid: 3851462
Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM, Patel T (2011) microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30:4750–4756
doi: 10.1038/onc.2011.193
pubmed: 21625215
pmcid: 4292930
Sun L, Li Y, Yang B (2016) Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53’s transcriptional activity. Biochem Biophys Res Commun 478:323–329
doi: 10.1016/j.bbrc.2016.05.031
pubmed: 27166155
Qin N, Tong GF, Sun LW, Xu XL (2017) Long noncoding RNA MEG3 suppresses glioma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of miR-19a. Oncol Res 25:1471–1478
doi: 10.3727/096504017X14886689179993
pubmed: 28276316
pmcid: 7841124
Li Z, Li C, Liu C, Yu S, Zhang Y (2015) Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. Pituitary 18:42–47
doi: 10.1007/s11102-014-0554-0
pubmed: 24469926
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G, Santoro M, Chiariotti L, Fusco A (2001) High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 20:6132–6141
doi: 10.1038/sj.onc.1204635
pubmed: 11593421
Yoon JH, Srikantan S, Gorospe M (2012) MS2-TRAP (MS2-tagged RNA affinity purification): tagging RNA to identify associated miRNAs. Methods 58:81–87
doi: 10.1016/j.ymeth.2012.07.004
pubmed: 22813890
pmcid: 3493847
Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033–1038
doi: 10.1038/nature09144
pubmed: 20577206
pmcid: 3206313
D’Angelo D, Esposito F, Fusco A (2015) Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas. Front Med (Lausanne) 2:39
Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, Kenyon L, Visone R, De Martino I, Ciarmiello A, Arra C et al (2005) Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24:3427–3435
doi: 10.1038/sj.onc.1208501
pubmed: 15735694
Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7:899–910
doi: 10.1038/nrc2271
pubmed: 18004397
Pallante P, Sepe R, Puca F, Fusco A (2015) High mobility group a proteins as tumor markers. Front Med (Lausanne) 2:15
Šteňo A, Bocko J, Rychlý B, Chorváth M, Celec P, Fabian M, Belan V, Šteňo J (2014) Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth. Acta Neurochir 156:451–461; discussion 461
doi: 10.1007/s00701-014-1993-0
pubmed: 24452592
Esposito F, De Martino M, Petti MG, Forzati F, Tornincasa M, Federico A, Arra C, Pierantoni GM, Fusco A (2014) HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. Oncotarget 5:8341–8354
pubmed: 25268743
pmcid: 4226687
Esposito F, De Martino M, D’Angelo D, Mussnich P, Raverot G, Jaffrain-Rea ML, Fraggetta F, Trouillas J, Fusco A (2015) HMGA1-pseudogene expression is induced in human pituitary tumors. Cell Cycle 14:1471–1475
doi: 10.1080/15384101.2015.1021520
pubmed: 25894544
pmcid: 4615119
Forzati F, Federico A, Pallante P, Abbate A, Esposito F, Malapelle U, Sepe R, Palma G, Troncone G, Scarfò M, Arra C, Fedele M, Fusco A (2012) CBX7 is a tumor suppressor in mice and humans. J Clin Invest 122:612–623
doi: 10.1172/JCI58620
pubmed: 22214847
pmcid: 3266782
Fedele M, Fusco A (2010) Role of the high mobility group A proteins in the regulation of pituitary cell cycle. J Mol Endocrinol 44:309–318
doi: 10.1677/JME-09-0178
pubmed: 20219853
Seton-Rogers S (2013) Non-coding RNAs: the cancer X factor. Nat Rev Cancer 13:224–225
doi: 10.1038/nrc3489
pubmed: 23446546
Peng L, Yuan X, Jiang B, Tang Z, Li GC (2016) LncRNAs: key players and novel insights into cervical cancer. Tumour Biol 37:2779–2788
doi: 10.1007/s13277-015-4663-9
pubmed: 26715267
Kumar A, Birnbaum MD, Patel DM, Morgan WM, Singh J, Barrientos A, Zhang F (2016) Posttranslational arginylation enzyme Ate1 affects DNA mutagenesis by regulating stress response. Cell Death Dis 7:e2378
doi: 10.1038/cddis.2016.284
pubmed: 27685622
pmcid: 5059882